CTKB NASDAQ
Cytek Biosciences, Inc.
1W: +3.9%
1M: +25.2%
3M: +27.1%
YTD: +19.3%
1Y: +62.6%
3Y: -5.0%
5Y: -75.7%
$5.87
+0.06 (+1.03%)
Weekly Expected Move ±6.4%
$5
$5
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (33)
1,315,332 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Bank of America Corp DE
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
371,427 Shares in Cytek Biosciences, Inc. $CTKB Purchased by Bank of New York Mellon Corp
Deutsche Bank AG Makes New $496,000 Investment in Cytek Biosciences, Inc. $CTKB
Cytek (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Concrete Pumping Holdings Reports Blowout Q2 Results, Joins ServiceTitan and Other Big Stocks Moving Higher in Friday's Pre-Market Session
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Braze Posts Mixed Q1 Results, Joins Sidus Space, Everpure And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Cytek (CTKB) Q1 2026 Earnings Call Transcript
Cytek reaffirms $205M-$212M 2026 revenue outlook as U.S. growth rebounds
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
12 Health Care Stocks Moving In Thursday's After-Market Session
Analysts Set Cytek Biosciences, Inc. (NASDAQ:CTKB) PT at $5.38
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives $5.38 Consensus PT from Analysts
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives $5.50 Average PT from Brokerages
Cytek Biosciences outlines $205M–$212M 2026 revenue target amid record Q4 and growth in recurring revenue
Cytek Biosciences GAAP EPS of -$0.34 misses by $0.30, revenue of $62.1M beats by $3.3M
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Rating of “Hold” from Analysts
Bank of Montreal Can Boosts Stock Position in Cytek Biosciences, Inc. $CTKB
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth